Physician profile
Jesse Arellano
NPI 1285659284
$11,798.05
in general payments reported to CMS, 2019-2025
36 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $2,066 · 2021: $2,563 · 2022: $1,547 · 2023: $2,325 · 2024: $1,361 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,834.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,638.98 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,432.39 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,204.75 | 2019-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Abbvie INC. | $1,088.38 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $960.67 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $823.44 | 2019-2025 | |
| Lilly USA, LLC | $798.61 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $670.06 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $619.75 | 2022-2025 | |
| Amarin Pharma, INC. | $305.65 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $280.00 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $242.48 | 2021 | |
| Mannkind Corporation | $222.01 | 2021-2024 | Afrezza |
| Sanofi-Aventis U.S. LLC | $201.50 | 2019-2022 | |
| Allergan, INC. | $198.59 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Arellano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.